Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in relapsing or treatment-naive adult dermatomyositis
2020-004987-24Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Baricitinib + usual care with Placebo + usual care (2 arms). Primary endpoint: Prednisone-free moderate improvement at week 24. Started Dec 2020; status: active.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2020-004987-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004987-24.